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Abstract Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an 
aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains 
difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase 
from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. 
Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely 
dependent on FoxM1, a master mitotic transcription factor that is also found to be highly 
overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not 
luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells 
induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is 
not required for mouse development and physiology. Together, these data indicate that MELK is a 
normally non-essential kinase, but is critical for BBC and thus represents a promising selective 
therapeutic target for the most aggressive subtype of breast cancer.
DOI: 10.7554/eLife.01763.001
Introduction
Breast cancer is a heterogeneous disease with a high degree of diversity in histology, therapeutic 
response, and treatment outcomes. Transcriptional profiling analyses have reproducibly identified at 
least five major ‘intrinsic’ subtypes of breast cancer: normal breast-like, luminal A, luminal B, HER2/
Neu-enriched, and basal-like breast cancer (BBC) (Perou et al., 2000; Sorlie et al., 2001). These mo-
lecular subtypes have recently been confirmed in a comprehensive characterization of human breast 
tumors at the genomic, epigenetic, transcriptomic, and proteomic levels (Cancer Genome Atlas 
Network, 2012). Among these subtypes, basal-like breast cancer (BBC) is strongly associated with 
an aggressive phenotype and poor prognosis (Rakha et al., 2008). Unlike their luminal counterparts, 
BBC cells lack expression of estrogen receptor (ER) and progesterone receptor (PR). Most BBC tumors 
also lack expression of HER2 and thus this subtype largely overlaps with the clinically defined ‘triple-
negative’ breast cancer (TNBC), which is also characterized by the lack of ER, PR, and HER2 expression 
(Rakha et al., 2008; Foulkes et al., 2010). The lack of these molecular targets renders BBC or TNBC 
cells relatively unresponsive to the targeted therapies that are highly effective in the treatment of 
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luminal or HER2 positive breast cancer. Thus, establishing the molecular pathogenesis of this subtype 
and identifying potential targets for treatment remains a key challenge for BBC/TNBC.
Kinases comprise a large family of proteins that is frequently involved in tumor pathogenesis. 
Indeed, a large number of mutations, alterations in copy number, and/or expression level have been 
observed in genes encoding kinases across multiple types of human cancers. In addition, kinases have 
proven to be pharmacologically tractable, making inhibition of kinase activity with small molecules a 
highly effective strategy for cancer treatment (Zhang et al., 2009). Therefore, identifying kinases crit-
ical for the growth and survival of BBC cells could not only provide valuable insights into the patho-
genesis of BBC, but also define potential druggable targets for therapeutic interventions.
Kinases that regulate progression through mitosis, including Aurora A, Aurora B and PLK1, are 
essential for cell proliferation. Inhibiting them in cancer cells causes mitotic arrest and/or abnormalities 
in chromosome segregation and cytokinesis, which in turn trigger apoptosis (Taylor and Peters, 2008; 
Lens et al., 2010). Inhibitors of these kinases are effective at eradicating human cancer cells in culture 
and in mouse xenograft models, but their efficacy in the clinic has been limited by killing of normal 
proliferating cells especially the bone marrow (Dar et al., 2010). If a kinase exists that is required for 
mitosis in a specific type of cancer cell, but not other tumor cells or in normal cells, inhibitors of that 
kinase might make highly effective and safe drugs. To date, this type of cancer-specific mitotic kinase 
has not been identified for any cancer.
In this study, we report the identification of MELK as a novel oncogenic kinase that emerged from 
an in vivo tumorigenesis screen. Analyses of breast cancer patient data according to subtypes revealed 
a remarkable overexpression of MELK in BBC. We further demonstrate that MELK is directly regulated 
by the FoxM1 transcription factor, a master mitotic regulator also found to be overexpressed in BBC. 
We discover that MELK is essential in basal-like, but not in luminal breast cancer cells. Notably, mice in 
which MELK has been genetically ablated display normal development and hematopoiesis. Together, 
our data establish MELK as a mitosis-regulating kinase involved in the pathogenesis of BBC and a 
promising molecular target for patients with basal-like breast malignancy.
eLife digest Not all cancers are the same. There are, for example, at least five types of breast 
cancer. Different types of cancer can have different mutations and express different genes that 
determine how aggressively the tumors grow and how well they respond to different therapies. By 
exploiting these differences, scientists have developed therapies that target specific tumor types, 
and these targeted therapies have proven useful against most breast cancers.
One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows 
rapidly and there are few treatment options for women with this type of cancer. One reason for this 
is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that 
are the targets of existing therapies.
Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can  
kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are 
safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, 
cancer researchers have been searching for a kinase that is active in cancer cells but not in normal 
cells.
Wang et al. tested a large collection of kinases and found that one called MELK caused tumors 
to grow in the mammary glands of mice. Further examination of tumor samples collected from 
hundreds of women in previous clinical studies revealed that MELK expression was increased in 
basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor 
targets.
When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK 
working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells 
that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy 
mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these 
mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill 
basal-like breast cancer cells without having the side effect of harming normal cells.
DOI: 10.7554/eLife.01763.002Cell biology | Human biology and medicine
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Results
Identification of oncogenic kinases that contribute to tumorigenesis of 
HMECs in vivo
Transformation of primary human cells with defined genetic elements is a powerful method for identi-
fying specific genes or pathways that are involved in oncogenic transformation (Hahn et al., 1999; 
Zhao et al., 2004). To this end, we first developed an in vivo tumorigenesis system that models the 
pathogenesis of human breast cancer, using a previously established human mammary epithelial cell 
(HMEC)-based transformation system (Zhao et al., 2003). To further optimize this system, we engi-
neered telomerase-immortalized HMECs to express a dominant negative form of p53 (p53DD), NeuT 
and PI3KCA H1047R. The resulting cells, termed HMEC-DD-NeuT-PI3KCA, were fully transformed 
as evaluated by their ability to form orthotopic tumors in the mammary fat pads of mice (Figure 1—
figure supplement 1). Our model recapitulates the concurrent activation of HER2/Neu and PI3KCA 
that is prevalent in breast cancer (Stephens et al., 2012).
The HMEC transformation system described above provided us with a platform to identify novel 
oncogenic events capable of replacing the mutant PIK3CA in cooperating with NeuT to drive HMECs 
to form tumors in mice. To this end, we infected HMEC-DD-NeuT cells (lacking the mutant PIK3CA) 
with subpools of a kinome-wide retroviral library consisting of 354 human kinases and kinase-related 
open reading frames (Boehm et al., 2007). The library was screened as a series of subpools of 10–12 
kinase ORFs in HMEC-DD-NeuT cells. The infected cells were injected into the inguinal mammary fat 
pads of mice, and recipient mice were followed for tumor formation. Kinases in 12 pools induced 
tumor formation with latencies of 2–4 months. Genomic DNA was extracted from harvested tumor 
specimen as well as HMECs infected with matched pools of kinases prior to injection. We then used 
quantitative PCR to determine the relative abundance of each kinase in these paired samples. In total, 
26 kinases were found specifically enriched in the tumors in vivo (Figure 1, Figure 1—figure supple-
ment 2). Several candidate kinases that scored in the screen have previously been implicated as proto-
oncogenes or cancer-associated genes, such as the inhibitor of nuclear factor kappa-B kinase subunit 
epsilon (IKBKE) (Boehm et al., 2007), rearranged during transfection (RET) (Takahashi et al., 1985), 
casein kinase 1 epsilon (CSNK1E) (Kim et al., 2010), NIMA-related serine/threonine kinase 6 (NEK6) 
(Nassirpour et al., 2010), and polo-like kinase 1 (PLK1) (Liu et al., 2006). At least three of them, PLK1 
(Golsteyn et al., 1994), NEK6 (Yin et al., 2003), and MELK (maternal embryonic leucine zipper kinase) 
(Le Page et al., 2011), have been previously implicated in regulating mitotic progression.
MELK is highly overexpressed in human breast cancer and its 
overexpression strongly correlates with poor disease outcomes
One of the top-scoring hits from our genetic screen was MELK (Figure 1), an atypical member of 
AMPK serine/threonine kinase family (Lizcano et al., 2004). While little is known about the exact 
biological functions of MELK, this kinase has been reported to be overexpressed in a variety of tumors 
(Gray et al., 2005). When we analyzed MELK expression in the breast cancer data set of The Cancer 
Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2012), a large cohort consisting of 392 inva-
sive ductal breast carcinomas and 61 samples of normal breast tissues, the level of MELK transcript 
was approximately eightfold higher in breast tumors compared to their normal counterparts (Figure 2A). 
The p value for this differential expression (4.6 × 10−54) places MELK in the top 1% overexpressed 
genes in breast cancer (Figure 2A). The overexpression of MELK in breast tumors relative to normal 
breast tissues was further confirmed by analyzing two other independent data sets (Figure 2—figure 
supplement 1A; Ma et al., 2009; Richardson et al., 2006).
To gain insights into the potential relevance of MELK overexpression in breast cancer, we asked 
whether MELK expression correlates with the status of disease. By analyzing gene expression data 
across five independent cohorts totaling more than 1500 patients (Desmedt et al., 2007; Hatzis 
et al., 2011; Schmidt et al., 2008; Wang et al., 2005b; Supplementary file 1), we found that higher 
expression of MELK was strongly associated with higher histologic grade in breast cancer (Figure 2B, 
Figure 2—figure supplement 1B); the p values for this correlation rank in the top 1% of a total 12,624 
or more genes measured in all these cohorts.
We also examined whether MELK expression is correlated with metastatic recurrence. We analyzed 
three independent cohorts in which patients with early-stage breast cancer were followed for metastasis-
free survival and had not received adjuvant systemic treatment after surgery (van 't Veer et al., 2002; Cell biology | Human biology and medicine
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Wang et al., 2005b; Schmidt et al., 2008; Supplementary file 1). In all three cohorts, higher MELK 
expression levels were strongly associated with earlier metastasis in women initially diagnosed with 
lymph-node-negative tumors (all p values<0.001, hazard ratios >2; Figure 2C, Figure 2—figure 
supplement 1C). We further analyzed two cohorts, where a majority of patients had high grade and 
lymph-node-positive breast cancer and nearly all patients received neoadjuvant chemotherapy and/or 
hormone therapy (Hatzis et al., 2011; Loi et al., 2007; Supplementary file 1). Again, high expression 
level of MELK robustly correlates with metastasis in breast cancer patients (both p values<0.001, haz-
ard ratios >2; Figure 2C). Thus MELK overexpression appears to have a strong predictive value for 
breast cancer metastasis irrespective of tumor grade or treatment regimen.
We next asked if MELK expression also correlates with the survival of breast cancer patients. In five 
independent large cohorts in which more than 1100 total patients were followed for overall survival 
(Desmedt et al., 2007; Esserman et al., 2012; Kao et al., 2011; Pawitan et al., 2005; van de Vijver 
Figure 1. An in vivo kinome-wide screen identifies MELK as a potential oncogenic kinase. Pools of retroviral vectors 
encoding 354 human kinases and kinase-related proteins (37 pools in total, each consisting of 10–12 unique open 
reading frames) were transduced into HMED-DD-NeuT cells. After selection with neomycin, cells were transplanted 
into mammary fat pads of nude mice. Tumors that formed from HMECs infected with 12 pools of kinases were 
harvested, and genomic DNA was extracted. qPCR was performed on genomic DNA from the tumor specimens 
and cells infected with matched pools of kinases before injection. The relative fold enrichment was calculated from 
the differences in Ct value.
DOI: 10.7554/eLife.01763.003
The following figure supplements are available for figure 1:
Figure supplement 1. Development of an in vivo tumorigenesis model. 
DOI: 10.7554/eLife.01763.004
Figure supplement 2. Screen hits and their gene description. 
DOI: 10.7554/eLife.01763.005Cell biology | Human biology and medicine
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Figure 2. MELK is highly overexpressed in breast cancer and its overexpression strongly correlates with poor 
prognosis. (A) MELK expression levels are significantly higher in breast carcinoma (n = 392, red circles) than in 
normal breast tissues (n = 61, blue circles) in the TCGA breast cancer cohort (Cancer Genome Atlas Network, 
2012). Black lines in each group indicate median with interquartile range. p=4.6 × 10−54 (Student's t test). (B) Expression 
level of MELK tightly correlates with the pathological grade of breast tumors in the three independent cohorts for 
which these data are available. Black lines in each group indicate median with interquartile range. p values were 
calculated with one-way ANOVA. (C) Kaplan–Meier analysis of metastasis-free survival of breast cancer patients in 
two independent cohorts. Samples were divided into two groups with high and low expression levels of MELK.  
p values were obtained from the log-rank test. Hazard ratio (HR) was calculated using GraphPad Prism.  
Figure 2. Continued on next pageCell biology | Human biology and medicine
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et al., 2002; Supplementary file 1), high expression level of MELK strongly correlated with increased 
rates of mortality (all p values<0.05, hazard ratios >2) (Figure 2D, Figure 2—figure supplement 1D). 
Together, these data show that MELK may serve as a prognostic indicator in predicting breast cancer 
patients' likelihood of metastasis and overall survival rate.
MELK is commonly overexpressed in the subtype of basal-like breast 
tumors
Given the heterogeneity of breast cancer, we analyzed MELK expression in different subtypes of 
breast cancer as defined by gene expression profiling (Perou et al., 2000; Sorlie et al., 2001). We 
categorized samples in multiple breast cancer data sets by PAM50 gene signature (Parker et al., 
2009). In five independent cohorts with more than 1500 patients in total, we observed a strikingly 
similar pattern of MELK expression among these different subtypes of breast tumors (Figure 2E, 
Figure 2—figure supplement 1E). While luminal A and normal-like subtypes displayed the lowest 
expression of MELK, basal-like breast cancers (BBC) showed the highest expression level of MELK 
among all subtypes (p<0.0001). Given that there are more high-grade tumors in the BBC than the 
other subtypes, we sought to determine the correlation of MELK with subtypes of breast tumors within 
the same grade. We performed statistical analysis of a large cohort of breast cancer for grade 1, 2 and 
3 across all subtypes, respectively, and found that MELK is most highly expressed in BBC (Figure 2—
figure supplement 2A), suggesting that MELK expression is most pronounced in basal-like breast 
tumors with the same pathological grade. Moreover, a significant association of MELK expression with 
disease status also exists within the subtype of BBC (Figure 2—figure supplement 2B), suggesting 
that MELK expression is associated with tumor aggressiveness and poor prognosis in this disease.
Consistent with this observation of MELK overexpression in BBC, we found that MELK expression 
in breast tumors has a significant inverse correlation with the expression of luminal markers, including 
estrogen and progesterone receptors (ER, PR) (Figure 2F, Figure 2—figure supplement 1F). To con-
firm this observation at the protein level, we analyzed primary tumors samples for MELK expression. 
Strikingly, all the four ER/PR+ tumor samples lacked detectable signal of MELK expression. In contrast, 
ER/PR-negative tumors had abundant MELK protein (Figure 2G). Given that ER/PR expression varies 
within the molecular HER2+ subtype, we analyzed MELK expression within this subtype. We found 
that MELK expression was significantly higher in ER/PR− tumors than in those with ER/PR+ status 
(Figure 2H).
An alternate categorization of breast cancers uses the expression of ER/PR and HER2. Triple-
negative breast cancer (TNBC), a subtype lacking ER/PR and HER2 expression, largely overlaps with 
basal-like breast cancer (Rakha et al., 2008; Foulkes et al., 2010). Because this subtype-categorization 
(D) Kaplan–Meier analysis of overall survival in the van de Vijver cohort breast cancer patients. Samples were 
divided as in (C). Log-rank p value and hazard ratio (HR) are shown. (E) MELK expression among the molecular 
subtypes of breast cancer. Samples in each cohort were classified into five distinct molecular subtypes using PAM50 
(Parker et al., 2009). Black lines in each group indicate median with interquartile range. (F) MELK expression 
inversely correlates with that of estrogen receptor (ER) or progesterone receptor (PR). Linear regression was 
determined using GraphPad Prism. The linear regression Pearson's correlation coefficient (R2) and its p value are 
indicated. (G) ER/PR− breast tumors have higher abundance of MELK protein than ER/PR+ ones. Lysates of primary 
human tumors were subjected to immunoblotting using the indicated antibodies. (H) Expression of ER/PR 
determines MELK expression within HER2+ breast cancer. Samples with molecular HER2+ status were classified 
into ER/PR+ and ER/PR− groups. Black lines in each group indicate median with interquartile range. (I) MELK 
expression in subtypes of breast cancer that are defined by ER/PR, and HER2 expression. Note that HER2+ tumors 
were divided into ER/PR+ and ER/PR− groups. *p<0.05, ****p<0.0001 (Student's t test).
DOI: 10.7554/eLife.01763.006
The following figure supplements are available for figure 2:
Figure supplement 1. MELK is a top-ranking overexpressed gene in breast cancer and a strong prognostic 
indicator. 
DOI: 10.7554/eLife.01763.007
Figure supplement 2. Correlation of MELK expression with breast cancer subtypes and the histologic grade of 
disease. 
DOI: 10.7554/eLife.01763.008
Figure 2. ContinuedCell biology | Human biology and medicine
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has been routinely used in the clinic for diagnosis and selection of treatment strategies, we also exam-
ined whether MELK expression correlates with this alternate subtype categorization. In two inde-
pendent cohorts, the expression level of MELK is the highest in TNBC (Figure 2I, Figure 2—figure 
supplement 1G). Again, within the HER2+ sub-group, ER/PR− tumors have much higher MELK 
expression than ER/PR+ ones (Figure 2I). Together, these data indicate that MELK expression is 
highly elevated in breast tumors lacking the expression of ER and PR luminal markers.
FoxM1 is overexpressed in BBC and regulates MELK expression
To investigate the mechanism underlying MELK overexpression in BBC, we first analyzed the copy 
number of MELK in breast cancer. Gene amplification of MELK occurs in both primary tumors and 
human breast cancer cell lines, especially in ER-negative samples (Figure 3—figure supplement 1). 
These tumors or cells with increased copy number of MELK also exhibit high level of MELK expression, 
suggesting that gene amplification contributes to the overexpression of MELK.
However, gene amplification of MELK occurs at low frequency, and does not explain the wide-
spread overexpression of MELK in BBC. Recent comprehensive profiling of breast cancer suggests a 
role for FoxM1 activation in the transcriptional maintenance of BBC (Cancer Genome Atlas Network, 
2012). We found that like MELK, FoxM1 is most highly expressed in the BBC or TNBC subtypes 
(Figure 3A, Figure 3—figure supplement 2A,B). Moreover, an extremely tight correlation between 
FoxM1 and MELK expression was observed in multiple large-sized cohorts (Figure 3B, Figure 3—
figure supplement 2C). FoxM1 downregulation via gene silencing or a chemical inhibitor, thiostrep-
toin (Hegde et al., 2011), reduced MELK expression (Figure 3C,D, Figure 3—figure supplement 2D). 
Furthermore, we found that the promoter of MELK contains a putative FoxM1 binding motif (Wierstra 
and Alves, 2007), and chromatin immunoprecipitation assays using a FoxM1-specific antibody recov-
ered a MELK promoter region that included the putative binding site (Figure 3E). Together these 
data suggest that FoxM1 is a transcription factor that is enriched in BBC and regulates MELK expres-
sion, providing a molecular mechanism underlying the overexpression of MELK in BBC.
Given that FoxM1 is a master transcription factor for many genes that are essential for mitosis 
(Laoukili et al., 2005; Wang et al., 2005a), our finding also suggests that MELK is a mitotic factor in 
BBC cells. Proteins required for mitotic progression typically accumulate during G2 and M phase, and 
are destroyed by ubiquitin-dependent proteolysis at the end of cytokinesis. A previous study reported 
that MELK is stabilized in mitosis and partially degraded upon mitotic exit in HeLa cells and Xenopus 
embryos (Badouel et al., 2010). We found that, in BBC cells, MELK was highly expressed during mito-
sis, and its protein abundance decreased dramatically when mitotic cells progressed into G1 phase 
(Figure 3F, Figure 3—figure supplement 3). This expression pattern of MELK, which is similar to that 
of Cyclin B1 and Aurora kinases, indicates that MELK is a mitotic kinase in BBC cells. Interestingly, 
while luminal breast cancer cells have a similar pattern of MELK expression during cell cycle, their 
MELK protein levels in the M phase are much lower than those of BBC cells (Figure 3G). The expres-
sion levels of other mitotic factors including Cyclin B1 and Aurora A are comparable between basal-
like and luminal cancer cells (Figure 3G), suggesting that MELK may play a unique role during mitosis 
in BBC cells.
Overexpression of MELK displays robust oncogenic activity
MELK was scored in our kinase library screen and is overexpressed in breast cancer, particularly in 
basal-like breast tumors. Therefore, we sought to further determine the potential oncogenic role of 
MELK. To this end, we re-engineered HMEC-DD-NeuT cells to express wild type (WT-) or myristoylated 
(myr-) MELK (the kinases in our initial screen were myristoylated, Boehm et al., 2007). While HMEC-
DD-NeuT cells expressing the empty vector failed to form tumors in mice, overexpression of either 
WT- or myr-MELK in these cells drove tumor formation with 100% penetrance within 2 months 
(Figure 4—figure supplement 1), demonstrating that overexpression of MELK was able to confer 
the tumorigenicity of HMEC-DD-NeuT cells.
MELK expression strongly correlates with cell proliferation (Venet et al., 2011), indicating a 
functional role of MELK for cell growth. Indeed, we found that MELK overexpression in non-
transformed HMEC-DD cells resulted in increased cell proliferation in suspension culture (Figure 
4—figue supplement 2A). While oncogenic PIK3CA, Ras, or NeuT alone can induce colony formation 
of HMEC-DD cells in soft agar, two oncogenic events (e.g., PIK3CA plus NeuT), are usually required to 
fully transform HMEC-DD cells to form tumors in mice (Zhao et al., 2003, 2004). Similar to these Cell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  8 of 27
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Figure 3. FoxM1 is overexpressed in BBC and regulates the expression of MELK. (A) High expression of FoxM1  
in BBC. Samples in the indicated data sets were grouped into subtypes based on the PAM50 gene signature 
(Parker et al., 2009). ns, denotes not significant. *p<0.05, ****p<0.0001. (B) FoxM1 and MELK expression are 
Figure 3. Continued on next pageCell biology | Human biology and medicine
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oncogenes, over-expression of MELK alone can also promote anchorage-independent growth of 
HMEC-DD and MCF10A cells (Figure 4—figure supplement 2B–E). Likewise, wild-type MELK coop-
erates with a second oncogene, for example NeuT, to induce tumor formation in vivo.
In contrast to the transformation of HMEC-DD cells, one oncogenic event is sufficient to trans-
form Rat1 rodent fibroblasts expressing p53DD (Rat1-DD) cells, as indicated by both anchorage-
independent growth in vitro and tumor formation in vivo (Ni et al., 2012). To determine whether 
MELK has a transforming activity as a single event in this system, we engineered Rat1-DD cells 
expressing MELK (Rat1-DD-MELK), or PI3KCA H1047R (Rat1-DD-PI3KCA H1047R) as a positive con-
trol (Figure 4A). As expected, Rat1-DD cells transduced with an empty vector failed to grow as colo-
nies in soft agar or to form tumors in mice. Strikingly, Rat1-DD-MELK cells displayed a robust 
transformed phenotype comparable to Rat1-DD-PI3KCA H1047R cells, as evidenced by both colony 
growth in vitro and tumor formation in vivo (Figure 4B,C).
To determine whether the transforming ability of MELK requires its kinase activity, we introduced 
catalytically inactive alleles of MELK, D150A or T167A (Lizcano et al., 2004; Vulsteke et al., 2004), 
into Rat-DD cells. Unlike Rat1-DD-MELK cells, both Rat1-DD-MELK-D150A and Rat1-DD-MELK-T167A 
cells exhibited only limited growth in soft agar or in mice (Figure 4D–F). Together, these studies indi-
cate that MELK can be a potent oncogenic driver, when it is aberrantly overexpressed and that this 
oncogenic potential relies on its kinase activity.
MELK is essential for the proliferation of BBC cells
Since MELK is predominantly overexpressed in basal-like breast tumors, we sought to determine 
whether MELK plays a role in the proliferation of BBC cells. We first analyzed a set of breast cancer cell 
lines that mirror the molecular subtypes of clinical tumors (Neve et al., 2006), and found that the 
expression level of MELK is much higher in the cohort of 23 BBC cell lines than in the cohort of   
24 luminal breast cancer cell lines (Figure 5A). This is consistent with the expression pattern of MELK 
in primary human breast tumors. We also confirmed that the protein abundance of MELK is much 
higher in BBC cells compared to luminal cells (MCF7 and T47D) (Figure 5B). These cell lines thus, 
provide an excellent platform to assess potential roles of MELK in BBC.
tightly correlated. Expression of MELK was plotted against that of FoxM1. Each circle represents an individual 
sample of human breast carcinoma (n = 392 for TCGA dataset; n = 261 for Bittner dataset). Red and green circles 
represent basal-like breast tumors and all other subtypes of breast tumors, respectively. Correlation analysis was 
performed by GraphPad Prism. (C) FoxM1 knockdown suppresses MELK expression. Cells were transfected with 
either control siRNA or siRNA-targeting FoxM1. Lysates were harvested 3 days after transfection and subjected to 
immunoblotting. Aurora kinase A (AURKA), a known transcriptional target of FoxM1 (Lefebvre et al., 2010), was 
used as a positive control. (D) FoxM1 inhibition downregulates the expression of MELK. MDA-MB-231 cells were 
treated for the indicated time with vehicle or thiostrepton. Protein lysates were subjected to immunoblotting 
analysis of MELK and AURKA as indicated. (E) A putative FoxM1 binding site in the MELK promoter, and the FoxM1 
consensus binding site (left). Numbers for the nucleotides are relative to the transcription start site (+1) of MELK. 
Chromatin immunoprecipitation assay of the MELK promoter in MDA-MB-468 cells (right). Control rabbit IgG and 
an antibody against FoxM1 were used. Primers for the promoter region of CDC25B were used as a positive control. 
(F) Cell cycle-dependent expression of MELK. MDA-MB-231 cells were treated with nocodazole (100 ng/ml) for  
18 hr or not treated (Asynchronized, As). Nocodazole-arrested mitotic cells (M) were isolated by shake-off, and the 
attached cells enriched in G2 phase (G2) were harvested. A part of the mitotic cells were released into G1 phase 
after 4 hr of incubation (M + 4 hr). The left panel shows the flow cytometry analysis of cell cycle, and the right panel 
shows immunoblotting analysis of MELK and other cell cycle-specific proteins as indicated. (G) Expression of MELK 
and other mitotic factors during cell cycles in basal-like (MDA-MB-231) vs luminal (MCF7) breast cancer cells. Cell 
lysates were prepared as in (F).
DOI: 10.7554/eLife.01763.009
The following figure supplements are available for figure 3:
Figure supplement 1. Gene amplification of MELK in BBC. 
DOI: 10.7554/eLife.01763.010
Figure supplement 2. FoxM1 is overexpressed in BBC and transcriptionally regulates MELK. 
DOI: 10.7554/eLife.01763.011
Figure supplement 3. MELK expression in different cell cycle of BBC cells. 
DOI: 10.7554/eLife.01763.012
Figure 3. ContinuedCell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  10 of 27
Research article
Figure 4. Overexpression of wild-type MELK induces oncogenic transformation. (A) Immunoblotting analysis of 
Rat1-DD cells expressing vector, wild-type (WT) allele of human MELK, or an oncogenic allele of PIK3CA (H1047R). 
Expression of PIK3CA (H1047R) enhances Akt phosphorylation. β-tubulin serves as a loading control. (B) Overexpression 
of MELK confers anchorage-independent growth of Rat1-DD cells. The left panel shows representative bright-field 
images of the anchorage-independent growth of cells expressing MELK or PIK3CA H1047R. The bar graph 
represents means ± SD for three experiments. (C) Overexpression of MELK drives Rat1-DD cells to form tumors in 
vivo. Representative subcutaneous tumors arising from injected Rat1-DD cells expressing MELK or PIK3CA H1047R 
are shown (left). The tumor weights for each group are shown as a dot chart (right). (D) Immunoblotting analysis of 
Rat1-DD cells expressing vector, WT MELK or two kinase-inactive alleles of MELK: D150A or T167A. Note that 
MELK is c-terminally tagged with a Flag epitope. (E) Rat1-DD cells expressing kinase-inactive alleles of MELK 
(D150A or T167A), fail to grow as colonies in soft agar. The bar graph represents means ± SD for three experiments. 
(F) Rat1-DD cells expressing kinase-inactive alleles of MELK (D150A or T167A), fail to grow as tumors in vivo. The 
tumor weights for each group are shown as a dot chart (right). ***p<0.001, Student's t test.
DOI: 10.7554/eLife.01763.013
The following figure supplements are available for figure 4:
Figure supplement 1. MELK overexpression promotes tumorigenesis. 
DOI: 10.7554/eLife.01763.014
Figure supplement 2. MELK overexpression promotes oncogenic transformation in vitro. 
DOI: 10.7554/eLife.01763.015Cell biology | Human biology and medicine
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Figure 5. MELK is essential for the growth of basal-like breast cancer cells. (A) MELK expression levels are 
significantly higher in BBC cell lines than in luminal breast cancer cell lines. The MELK mRNA data in 23 established 
BBC and 24 luminal breast cancer cell lines were obtained from the Neve dataset (Neve et al., 2006) and are 
shown as a dot chart. (B) Immunoblotting analysis of MELK protein abundance in 6 basal-like and 2 luminal breast 
cancer cell lines. α-tubulin was used as a loading control. (C) Effects of inducible shRNA-mediated MELK silencing 
(tet-shMELK) in one BBC cell line, BT549. Immunoblotting analysis of MELK protein levels in the presence and 
absence of doxycycline is shown in the left panels. The middle and the right panels show the crystal violet staining 
Figure 5. Continued on next pageCell biology | Human biology and medicine
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of the plates and their respective quantification. The bar graphs indicate means ± SD for three experiments.  
(D) Effects of MELK knockdown on the proliferation of additional five BBC cell lines. Cells were treated as in (C). 
The bar graph indicates means ± SD for three experiments. (E) Luminal breast cancer cells are insensitive to MELK 
knockdown. The indicated five luminal breast cell lines were treated as in (C). Quantification of cell proliferation is 
shown (means ± SD). (F) WT but not a kinase-inactive allele of MELK rescues the impaired cell proliferation of BBC 
cells induced by MELK knockdown. The left panel shows immunoblotting analysis of MELK protein level in 
MDA-MB-468 cells carrying tet-shMELK, and expressing either shMELK resistant WT MELK (MELK-R) or kinase-
inactive MELK (MELK-R, T167A) in the presence and absence of doxycycline. Note that the exogenous MELK is 
tagged with Flag epitope. The middle and the right panels show, respectively, the crystal violet staining of the 
plates and their respective quantification. The bar graph indicates means ± SD for three experiments. *p<0.05, 
**p<0.01, Student's t test.
DOI: 10.7554/eLife.01763.016
The following figure supplements are available for figure 5:
Figure supplement 1. MELK knockdown in basal and luminal breast cancer cells. 
DOI: 10.7554/eLife.01763.017
Figure supplement 2. MELK knockdown does not affect the proliferation of HMECs. 
DOI: 10.7554/eLife.01763.018
Figure supplement 3. Generation of shMELK-resistant MELK cDNA (MELK-R). 
DOI: 10.7554/eLife.01763.019
Figure 5. Continued
To examine the role of MELK in the proliferation of these cells, we utilized a tetracycline-inducible 
gene knockdown technique in which shRNA transcription (and consequently target gene silencing) is 
induced upon exposure of the targeted cells to doxycycline (Wiederschain et al., 2009). Among the 
multiple inducible shRNAs that we generated to target MELK, two shRNAs were found to efficiently 
reduce MELK expression in cells treated with doxycycline (Figure 5C). We then stably introduced both 
shMELKs into basal or luminal breast cancer cell lines. Cell proliferation was measured upon induction 
of the shRNA in the presence of doxycycline. As hypothesized, MELK knockdown strongly impaired 
the growth of all six BBC cell lines tested, including BT549, MDA-MB-468, MDA-MB-231, MDA-MB-436, 
HCC70, and HCC1954 (Figure 5C,D, Figure 5—figure supplement 1A,B). In contrast, in five luminal 
breast cell lines, MELK knockdown with equivalent efficiency did not result in obvious inhibition on cell 
growth (Figure 5E, Figure 5—figure supplement 1A,B). Similarly, MELK knockdown had little effect on 
non-transformed HMECs, which have low level of MELK expression (Figure 4—figure supplement 2).
To further validate the essential role of MELK in BBC cells, we carried out rescue experiments with 
both WT and kinase inactive MELK. We found that the proliferation of MDA-MB-468 cells expressing 
shMELK was restored, when the MELK expression level in these cells was rescued by expression of a 
shMELK-resistant allele of MELK (MELK-R) (Figure 5F, Figure 5—figure supplement 3), confirming 
that the effects of shRNA are due to the specific knockdown of MELK. Notably, expression of a kinase 
inactive version of MELK-R, MELK-R (T167A), failed to restore cell proliferation in these cells (Figure 5F), 
indicating that kinase activity of MELK is critical for the proliferation of these BBC cells.
Loss of MELK causes defective mitosis and cell death in BBC cells
To understand the mechanism(s) underlying the MELK function in BBC cells, we examined how induc-
ible shRNA-mediated MELK depletion affects various cellular processes. In the presence of doxycy-
cline, BBC cells underwent cell death indicated by increased apoptotic markers, including cleaved 
caspase 3, cleaved PARP, and DNA fragmentation (Figure 6A,B, Figure 6—figure supplement 1A). 
zVad, a pan-caspase inhibitor, was able to rescue cell death, indicating an active role of caspases in 
executing cell death upon MELK depletion (Figure 6C, Figure 6—figure supplement 1B). In contrast, 
MELK knockdown has little effect on luminal tumor cells, such as MCF7 (Figure 6D). To complement 
our RNAi-mediated MELK knockdown studies, we used a recently developed chemical inhibitor of 
MELK, OTSSP167 (Chung et al., 2012), to evaluate the functional dependency on MELK by basal and 
luminal breast cancer cells. Consistently, OTSSP167 induced apoptotic cell death selectively in basal 
breast cancer cells (Figure 6—figure supplement 2A–C).
The finding that MELK is a mitotic kinase in BBC cells prompted us to hypothesize that the cell 
death observed upon MELK inhibition might be due to an altered cell cycle progression. MELK 
knockdown by doxycycline induced an accumulation of cells with 4n DNA content (Figure 6E, Cell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  13 of 27
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Figure 6. MELK downregulation induces apoptosis and impairs mitosis in BBC cells. (A) Immunoblotting analysis of 
MDA-MB-468 cells carrying a scrambled control or tet-shMELK in the presence and absence of doxycycline. Both 
cleaved PARP and Caspase-3 levels increased upon MELK downregulation. (B) MELK knockdown induces DNA 
Figure 6. Continued on next pageCell biology | Human biology and medicine
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fragmentation. MDA-MB-468 cells carrying scramble control or tet-shMELK were treated with or without doxcycline 
followed by fixation and staining with DAPI. The bright and punctate staining indicative of DNA fragmentation was 
only seen in cells carrying tet-shMELK in the presence of doxycycline (lower right panel). (C) A caspase inhibitor 
prevents MELK knockdown-induced cell death. MDA-MB-468 cells stably transduced with tet-shMELK were either 
untreated or treated with doxycycline for 4 days, and further treated with with zVad-fmk (40 μM) or vehicle during 
the last 2 days. Lysates from these cells were subjected to immunoblotting, with β-tubulin as a loading control.  
(D) MELK knockdown induces cell death selectively in BBC cells. The indicated cells were untreated or treated with 
doxycycline for 4 days followed by immunoblotting and imaging analyses. MELK knockdown induces increased 
level of cleaved PARP (left) and cell death (right) in BT549 but not in MCF7 cells. (E) MELK knockdown induces the 
accumulation of cells with 4n DNA content and G2/M arrest. MDA-MB-468 cells carrying tet-shMELK were treated 
or untreated with doxycycline for 5 days. Samples were prepared for cell cycle analysis and immunoblotting. The 
left panel shows representative cell cycle histograms; the middle indicates the quantification of % cells with 4n DNA 
content; and in the right panel, immunoblotting analysis shows that depletion of MELK increases the expression of 
G2/M specific proteins as indicated. (F) MELK knockdown induces bi- or multi-nucleated cells. MDA-MB-468 cells 
carrying tet-shMELK were treated or untreated with doxycycline for 4 days, followed by fixation and DAPI staining. 
Cells with mono-, bi-, or multi-nuclei were counted, and the data indicate % cells with two or more than two nuclei. 
Each circle in the histogram represents a single randomly selected field (total number of cells counted >500 for 
each group). The black lines indicate mean ± SEM. (G) MELK inhibition induces defective cell division. Fluorescent 
images were obtained from MDA-MB-468 cells carrying tet-shMELK as described in (F) stained with anti-β-tubulin 
(green) and DAPI (blue). (H) MDA-MB-468 cells stably transduced with tet-shMELK and Histone 2B-GFP were 
cultured in the presence or absence of doxycycline for 3 days, and then subjected to time-lapse imaging. Time is 
given in hours:minutes. In the absence of doxycycline, cells undergo normal mitosis (top panels). In the presence of 
doxycycline, binucleated cells (middle panels) and cells in metaphase (bottom panels) undergo cell death.
DOI: 10.7554/eLife.01763.020
The following figure supplements are available for figure 6:
Figure supplement 1. MELK inhibition induces cell death in MDA-MB-468 cells. 
DOI: 10.7554/eLife.01763.021
Figure supplement 2. MELK inhibition induces cell death selectively in basal-like breast cancer cells. 
DOI: 10.7554/eLife.01763.022
Figure supplement 3. MELK inhibition in BBC cells induces cell death and defective mitosis. 
DOI: 10.7554/eLife.01763.023
Figure 6. Continued
Figure 6—figure supplement 3A), indicating an induction of G2/M arrest or failure of cytokinesis. By 
immunoblotting, we found that cells exposed to doxycycline exhibited an elevation of Cyclin B1 and 
Aurora A kinase, two markers of G2/mitosis (Figure 6E, Figure 6—figure supplement 3A). We next 
used microscopy to define the cell division defect in more detail. Doxycycline induced a nearly 
twofold increase in the percentage of cells with two or more nuclei (Figure 6F,G, Figure 6—figure 
supplement 3B), indicating a failure of cytokinesis. Indeed, our time-lapse microscopic analysis 
revealed binucleated cells forming after impaired cytokinesis (Video 1). Furthermore, cells in which 
MELK had been depleted displayed asymmetric division (Figure 6G), characterized by an unequal 
allocation of cell mass into daughter cells. Interestingly, Caenorhabditis elegans with mutations in 
the MELK homologue, PIG-1, demonstrate impaired asymmetric cell division (Cordes et al., 2006), 
supporting a critical role of MELK in the late stage of cell division.
We next used time-lapse microscopy of GFP-Histone 2B expressing cells (Kanda et al., 1998) to 
determine whether apoptosis and defective mitosis due to MELK knockdown are functionally associ-
ated. Cell death events were dramatically increased upon MELK knockdown (5 out of 235 cells in 
control, 151 out of 317 in doxycycline-treated cells during 10 hr of imaging). Moreover, cell death 
events were often preceded by division abnormalities in doxycycline-treated populations. Cells with 
double nuclei, which had presumably failed cytokinesis, often underwent cell death (Figure 6H, middle 
panel; Video 2). Some cells with an apparently normal metaphase plate were unable to progress 
towards anaphase, instead entering into the process of cell death directly from mitosis (Figure 6H, 
bottom panel; Video 3). Overall, following MELK knockdown, out of 27 examples we noted 16 failed 
mitoses among which 10 proceeded to cell death after the formation of metaphase plate and six gave 
rise to binucleated cells. By contrast, mitosis in 36 out of a total of 37 control cells appeared normal 
(Figure 6H, top panel; Video 4). The morphological events associated with failed cell division and 
ensuing cell death resembled the previous reports of the effects of inhibiting essential mitotic kinase Cell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  15 of 27
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Video 1. This representative time-lapse video, related 
to Figure 6, shows a MDA-MB-468/tet-shMELK cell in 
the presence of doxycycline fails to undergo cytokinesis. 
The large frame indicates the initial position of the cell, 
and small frame its final position. Note that the cell 
progresses into mitosis, which ends with a double-
nuclei cell following failed cytokinesis. Frame rate is five 
frames per second. Time is given in hours:minutes.
DOI: 10.7554/eLife.01763.024
Video 2. This representative time-lapse video, related 
to Figure 6, shows that in the presence of doxycycline, 
MDA-MB-468/tet-shMELK/GFP-H2B cells with double 
nuclei undergo cell death. The two frames indicate two 
such cells. Frame rate is five frames per second. Time is 
given in hours:minutes.
DOI: 10.7554/eLife.01763.025
such as Aurora B (Keen and Taylor, 2009). 
Together, these data suggest a model in which 
BBC cells rely on MELK for proper mitosis; inhib-
iting MELK in these cells causes impaired mitosis 
and consequent cell death.
Therapeutic targeting of MELK in 
basal-like breast cancer
Since MELK is selectively required for the survival   
of BBC cells, we sought to determine whether 
MELK also supports the oncogenic growth of 
BBC cells using both in vitro colony formation and 
in vivo xenograft tumor growth assays. While 
MDA-MB-468 and MDA-MB-231 cells readily grew 
into macroscopic colonies in soft agar, MELK 
knockdown in these cells upon doxycycline treat-
ment caused a nearly complete inhibition in colony 
formation (Figure 7A). To determine whether MELK 
is also important for BBC cells to grow as tumors 
in vivo, we transplanted BBC cells expressing 
inducible shMELK into the mammary fat pads of 
athymic mice to allow orthotopic tumor forma-
tion. While all recipient mice in the control group 
without doxycycline treatment developed tumors 
within 2 months, mice treated with doxycycline 
immediately following transplantation failed to 
develop tumors (Figure 7B), suggesting that 
MELK is required for the proliferation of these 
BBC cells in vivo. To further examine whether MELK 
is required for the maintenance of established 
tumors, we administered doxycycline to mice 
bearing xenograft tumors derived from basal-like 
or luminal breast cancer cells. Remarkably, down-
regulation of MELK led to a substantial regression 
of tumors arising from BBC cells but had little 
effect on tumors derived from luminal cancer cells 
(Figure 7C,D, Figure 7—figure supplement 1).
To determine if the pharmacological inhibi-
tion of MELK would recapitulate the effect of 
MELK knockdown in xenografts, we administered 
OTSSP167 or vehicle control to mice that have 
tumors derived from basal or luminal breast can-
cer cell lines. While the growth of luminal breast 
tumors were largely unaffected by the treatment 
of OTSSP167, the chemical caused significant 
inhibition on the growth of basal breast tumors 
(Figure 7E,F). Together, these data indicate the 
MELK is selectively required for the oncogenic 
growth of BBC cells, and suggest that MELK inhi-
bition could be an effective approach in treating 
basal-like breast cancer.
While MELK has a critical role in basal-like 
breast cancer, it is not clear whether this kinase is 
important for the proliferation of normal cells or tissue growth in vivo. This question is critical to the 
toxicity of any potential MELK-targeted therapy. To address this question, we generated mice with 
germ-line knockout (KO) of Melk (Figure 7G). Notably, Melk-deficient mice are viable and appear Cell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  16 of 27
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Video 3. This representative time-lapse video, related 
to Figure 6, shows that in the presence of doxycycline, 
MDA-MB-468/tet-shMELK/GFP-H2B cells undergo 
mitosis but ending with asymmetric cell division (in the 
top frame) or cell death (in the bottom frame). Frame 
rate is five frames per second. Time is given in 
hours:minutes.
DOI: 10.7554/eLife.01763.026
Video 4. This representative time-lapse video, related 
to Figure 6, shows that in the absence of doxycycline, 
MDA-MB-468/tet-shMELK/GFP-H2B cells demonstrate 
efficient mitosis. Frame rate is five frames per second. 
Time is given in hours: minutes.
DOI: 10.7554/eLife.01763.027
normal without any noticeable phenotypes in the 
development of the embryos or adult mice. Both 
male and female mice are fertile and produce 
litters of normal size. A study by Hebbard et al. 
found a high activity of Melk promoter in mouse 
mammary progenitor cells (Hebbard et al., 2010). 
Therefore, we anticipated an impairment of 
mammary gland development in Melk KO mice. 
However, mammary glands from mice with Melk 
KO appear normal in both morphology and func-
tion (e.g., lactation).
Since bone marrow toxicity is a major side 
effect of most anti-cancer therapies and, in par-
ticular, of those drugs targeting mitotic kinases/
machinery, we characterized the immune system 
in Melk-deficient mice. We isolated cells from 
bone marrow, spleen and thymus, and analyzed 
immune cell populations including monocytes, 
neutrophils, B and T cells. We also analyzed the 
hematopoietic stem cells and various progenitor 
cells in the bone marrow. In both cases, virtually 
no differences were found between wild-type 
and KO mice (Figure 7H,I). Together, these data 
suggest that Melk is not essential for normal 
development and physiological functions in mice, 
providing compelling evidence for MELK as a 
highly selective target for therapeutic interven-
tion of basal-like breast cancer.
Discussion
Patients with basal-like breast cancer remain 
faced with limited treatment options due to the 
aggressive nature of the disease and the current 
lack of suitable molecular targets for thera-
peutic intervention. In this study, we report that 
MELK, a novel oncogenic kinase that emerged 
from an unbiased, in vivo tumorigenesis screen, 
may indeed be a therapeutic target in this tumor 
type. In a comprehensive analysis of databases 
with multiple cohorts of breast cancer, we find 
MELK to be highly overexpressed in breast can-
cer lacking the expression of ER/PR, including 
basal-like breast cancer. Remarkably, overex-
pression of wild-type MELK induces robust onco-
genic transformation both in vitro and in vivo 
with a transforming potency comparable to that 
of the highly oncogenic mutant allele of PIK3CA. 
Even more striking is the finding that only basal-
like, but not luminal breast cancer cells, depend 
on MELK for proliferation. In addition, the dis-
pensable nature of Melk in normal development 
and hematopoiesis in mice underlines its selec-
tive role in BBC. Notably, the kinase activity of MELK is required for its transforming activity as   
well as for the survival and proliferation of BBC cells. Thus, MELK is potentially a novel oncogenic 
driver of basal-like breast carcinoma and a promising target for small molecule-based therapeutic 
intervention.Cell biology | Human biology and medicine
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Figure 7. MELK is essential to sustain the oncogenic growth of BBC Cells. (A) Effects of MELK knockdown on 
anchorage-independent growth of BBC cells in soft agar. The left and middle panels show crystal violet staining, 
and bright-field images of the colonies respectively. The bar graphs indicate the means ± SD for three 
Figure 7. Continued on next pageCell biology | Human biology and medicine
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Our data point to a potential role for MELK as a marker in predicting disease outcome. In multiple 
independent breast cancer cohorts analyzed, we found a strong association of high expression levels 
of MELK with a higher grade of malignancy and an unfavorable prognosis regardless of the treatment 
modality. While high MELK expression seems to be a unique phenomenon for BBC in breast cancer, 
MELK overexpression has been associated with tumor aggressiveness and poor outcome in a number 
of other cancer types, including glioblastoma (Nakano et al., 2008), astrocytoma (Marie et al., 2008), 
and prostate cancer (Kuner et al., 2013). The prognostic feature of MELK expression is likely due to 
its correlation with cell proliferation. In fact, MELK and other proliferation-related genes are major 
components of multi-gene signature for predicting disease outcome. For example, a recent study 
developed a cell proliferation signature that consists of the top 1% genes whose expression is most 
positively correlated with that of proliferating cell nuclear antigen (PCNA). The authors found that 
adjusting breast cancer expression data for this cell proliferation signature causes a dramatic reduction 
in outcome association of most published breast cancer signatures (Venet et al., 2011). Notably, 
MELK expression strongly correlates with cell proliferation, and in fact is one of the top-ranking signa-
ture genes of cell proliferation that correlate with PCNA expression (Venet et al., 2011).
Previous studies demonstrated that, while MELK is a member of the AMPK family, it is not activated 
via phosphorylation by the tumor suppressor kinase LKB1 (Lizcano et al., 2004). Recombinant MELK 
expressed in bacteria is catalytically active (Davezac et al., 2002; Lizcano et al., 2004; Beullens et al., 
2005). Consistent with these findings, overexpression of wild-type MELK readily drives transforma-
tion in vitro and in vivo. This behavior is similar to that of other established proto-oncoproteins, such 
ERBB2 (Di Fiore et al., 1987; Hudziak et al., 1987), and Aurora A kinase (Bischoff et al., 1998; 
Zhou et al., 1998), the transforming activity of which is driven by overexpression of the wild-type 
protein. While a number of substrates have been proposed for MELK, such as Bcl-G (Lin et al., 2007), 
CDC25B (Davezac et al., 2002), p53 (Seong and Ha, 2012), and PDK1 (Seong et al., 2012), the 
substrates that mediate the oncogenic activity of MELK in breast cancer remain to be identified.
An intriguing question is how the selective overexpression of MELK is achieved in BBC. Our finding 
that the mitotic transcription factor FoxM1 (Laoukili et al., 2005; Wang et al., 2005a) plays a major 
role in regulating MELK expression has shed some light on this enigma. Notably, the expression levels 
experiments. (B) Effects of MELK knockdown on the growth of BBC cells in vivo. MDA-MB-468 and MDA-MB-231 
cells carrying tet-shMELK were orthotopically implanted into the mammary fat pads of nude mice. The recipient 
mice were divided into two groups: one group of mice was given doxycycline-supplemented drinking water on the 
second day of injection for the duration of the experiment, while the other group of mice was maintained without 
doxycycline. The histogram indicates tumor volume measured 7 weeks after treatment. Data are means ± SEM (n ≥ 6). 
(C and D) Effects of MELK knockdown on established tumors arising from implantation of basal (C) or luminal (D) 
breast cancer cells. Mice bearing orthotopic tumors arising from the indicated cells carrying tet-shMELK were 
divided into two groups, with one group of mice receiving doxycycline, and the other maintained without doxycycline. 
Tumor volumes were measured on the indicated days after the administration of doxycyline. Data are means ± SEM 
(n ≥ 8). (E and F) Effects of MELK inhibition on tumor growth. Mice with tumors developed from basal (E) or luminal 
(F) breast cancer cells, were treated once daily with vehicle (0.5% methycellulose) or OTSSP167 (5 mg/kg). Tumor 
volumes were measured on the indicated days. Data are means ± SEM (n ≥ 8). (G) Knocking out Melk in mice. 
Indicated tissues were harvested from wild type or Melk−/− adult mice, and homogenized in RIPA lysis buffer. Lysates 
were subjected to immunoblotting. Total lysate of human breast cancer cell line MDA-MB-231 was used as a 
control. (H) Loss of Melk has no obvious impact on the development of immune system. Cells were isolated from 
bone marrow (BM), spleen and thymus, and subjected to flow cytometric analysis. Note that CD11b+/Gr1+ is a 
marker for neutrophils, CD11b+/Gr1− for monocytes, B220 for B cells, CD3, CD4 and CD8 for T cells. (I) Bone 
marrow was collected from wild type (wt) and Melk−/− (KO) mice and stained for the indicated cell populations. LSK: 
Lin−Sca1+ ckit+; LT-HSC(long-term hematopoietic stem cells): LSK CD150+CD48−; ST-HSC(short-term hemato-
poietic stem cells): LSK CD150−CD48−; CMP(Common myeloid progenitor): Lin−cKit+Sca1−IL7Ra−CD34+FcRg−; 
GMP(Granulocyte-macrophage progenitors): Lin−cKit+Sca1−IL7Ra−CD34+FcRg+; MEP(Megakaryocyte-erythrocyte 
progenitors): Lin−cKit+Sca1−IL7Ra−CD34−FcRg−; CLP(Common lymphoid progenitors): Lin−cKitmidSca1midIL7Ra+. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, Student's t test.
DOI: 10.7554/eLife.01763.028
The following figure supplements are available for figure 7:
Figure supplement 1. Efficient conditional MELK knockdown in vivo. 
DOI: 10.7554/eLife.01763.029
Figure 7. ContinuedCell biology | Human biology and medicine
Wang et al. eLife 2014;3:e01763. DOI: 10.7554/eLife.01763  19 of 27
Research article
of FoxM1 and MELK demonstrate a striking correlation across all breast cancer samples and sub-
types examined. Like MELK, FoxM1 is significantly overexpressed in BBC. Consistent with our results, 
FoxM1 was recently proposed as a transcriptional driver of proliferation-associated genes in BBC 
(Cancer Genome Atlas Network, 2012).
However, why MELK is selectively required for cell division in BBC cells, but not in other types of 
breast cancer or normal cells, remains an open question. MELK was not observed as a hit in systematic 
screens for essential cell division proteins in HeLa cells (Kittler et al., 2004). Both C. elegans and mice 
are tolerant of mutation or deletion of MELK ortholog (Cordes et al., 2006; Figure 7G–I). However, 
MELK can be essential in some circumstances. It is expressed in early frog embryos, where it seems to 
play some role in cell division (Le Page et al., 2011), and we observed it accumulating in dividing cells 
(Figure 3F), and playing an important role during cell division in BBC cells (Figure 6). To reconcile 
these apparently disparate findings, we propose that one or more MELK-related kinase is required for 
cell division in many, if not all vertebrate cells. In BBC cells, MELK must play this role uniquely and is 
selectively overexpressed, perhaps because redundant kinases are down-regulated. In other cells, 
MELK may function during division, but it is not essential due to redundancy with related kinases. 
Consistent with this hypothesis, the MELK-related kinase AMPK was recently shown to play a role in 
mitosis (Vazquez-Martin et al., 2009). Perhaps AMPK, or other kinases in the same family, can substi-
tute for MELK in some cells, but not in BBC cells, which seem to have become addicted to MELK for 
proper execution of cell division. Determining the precise function of MELK in cell division, and the 
reason this function is selectively required in BBC cells, will require further analysis. Nevertheless, our 
studies firmly establish MELK as a molecular target for the treatment of BBC. Unlike other mitotic factors 
like Aurora A, Aurora B, and PLK1, that are normally essential, MELK presents a unique mitotic kinase 
that is only required by a subset of cancer cells, and is therefore an excellent therapeutic target.
In summary, recent comprehensive characterization of basal-like breast cancer demonstrates that 
this subtype of disease has high genetic heterogeneity, but lacks commonly occurring genetic altera-
tions, with the exception of the frequent inactivation of p53 (Cancer Genome Atlas Network, 2012). 
In contrast, the relative uniform overexpression of MELK in basal-like breast cancer makes it a potential 
common target in an otherwise heterogeneous disease. Thus our data on MELK provide important 
information for guiding the development of targeted therapies in basal-like breast cancer.
Materials and methods
Plasmids
The human MELK was amplified using the template DNA deposited in the described kinase library, 
and cloned into pWZL retroviral vector (Zhao et al., 2003), in which target gene expression is driven 
by the long terminal repeat of Moloney murine leukemia virus. The MELK mutants (D150A, T167A, or 
shMELK-resistant MELK with silent mutations) were generated via Quickchange XL Site-directed 
Mutagenesis (Stratagene, La Jolla, CA). Primers were listed in Supplementary file 2.
To construct a tetracycline-inducible gene expression system, GFP or mutated MELK was amplified 
using the primers listed in Supplementary file 2. The PCR products were digested with AgeI and PacI, 
and ligated with digested pLKO-TREX (Wee et al., 2008).
To construct pWzl-H2B-GFP, human Histone 2B was amplified using the genomic DNA of HEK293T 
cells as templates. Primers for cloning were listed in Supplementary file 2. PCR products following 
digestion with BamHI and XhoI were ligated with digested pWzl-GFP.
To generate pLKO-tet-on-shRNAs targeting human MELK, oligonucleotides were designed and 
synthesized (IDT, Coralville, Iowa). Following annealination, double-stranded oligonucleotides were 
directly ligated with pLKO vector that was digested with AgeI and EcoRI. The sequences for scramble, 
shMELK1, shMELK2 are listed in Supplementary file 2.
Retroviruses were generated by transfecting HEK293T cells with pWzl plasmids and packaging 
DNA. Typically 1.6 μg pWzl DNA, 1.2 μg pCG-VSVG and 1.2 μg pCG-gap/pol, 12 μl lipid of Metafectene 
Pro (Biontex, Martinsried, Germany) were used; DNA and lipid were diluted in 300 μl PBS respectively 
and mixed; and following 15 min of incubation, they were added to one 6-cm dish that was seeded with 
3 million HEK293T cells 1 day earlier. Viral supernatant was collected 48 hr and 72 hr after transfection. 
After the supernatant was filtered through 0.45-μm membrane, it was added to target cells in the pres-
ence of 8 μg/ml polybrene (Millipore, Billerica, MA). Lentiviruses were generated with a similar approach 
with the exception of HEK293T cells that were transfected with 2 μg pLKO DNA, 1.5 μg pCMV-dR8.91, Cell biology | Human biology and medicine
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and 0.5 μg pMD2-VSVG. Cells were selected with antibiotics starting 72 hr after initial infection. 
Puromycin and blasticidin were used at the final concentrations of 1.5 μg/ml and 4 μg/ml respectively.
Cell culture
Human mammary epithelial cells (HMECs) were maintained in DMEM/F-12 supplemented with 
EGF (10 ng/ml), insulin (10 μg/ml), and hydrocortisone (0.5 μg/ml) under 5% CO2 and 37°C. Rat1 and 
HEK293T cells were maintained in DMEM supplemented with 10% FBS (Invitrogen, Carlsbad, CA). All 
breast cancer cell lines (MCF7, T47D, MDA-MB-468, MDA-MB-231, MDA-MB-436, HCC1197, BT549) 
were cultured in RPMI 1640 medium supplemented with 10% FBS. For cells stably introduced with 
tetracyclin-inducible genes/shRNAs, Tet-approved FBS (Clontech, Mountain View, CA) was used.
Cell proliferation assay
Typically, breast cancer cells were seeded in 12-well plates (1–2 × 104) in 1 ml medium. On the next 
day, wells were added with 110 μl medium without or with 1 μg/ml doxycycline (to reach a final con-
centration of 100 ng/ml), which was repeated every 2 days. 6 days after the initial treatment, cells were 
fixed with formaldehyde, and stained with crystal violet (0.05%, wt/vol), a chromatin-binding cyto-
chemical stain. The plates were washed extensively, and imaged with a flatbed scanner. For quantifi-
cation of the staining, 1 ml 10% acetic acid was added to each well to extract the dye. The absorbance 
was measured at 590 nm with 750 nm as a reference.
Colony formation assay
The assays were typically performed in a 12-well plate unless otherwise mentioned. Cells were sus-
pended in medium containing 0.3% agar and plated onto a layer of 0.6% agar (for each well, 4000 cell 
in 800 μl medium, 1 ml bottom agar). The wells were added with medium (without or with 100 ng/ml 
doxcycycline) on the next day. 3 weeks after seeding, the colonies were fixed with formaldehyde and 
imaged. The number of colonies in each well was quantified using ImageJ (National Institutes of Health).
Tumor xenograft studies
All xenograft studies were conducted in accordance with the animal use guidelines from the 
National Institutes of Health and with protocols approved by the Dana-Farber Cancer Institute Animal 
Care and Use Committee. The recipient mice used were NCR-nude (CrTac:NCr-Foxn1nu, Taconic, 
Hudson, NY). Cells were resuspended in 40% of Matrigel-Basement Membrane Matrix, LDEV-free 
(BD Biosciences, San Jose, CA) and sit on ice until injection. For transplanting human cell lines, mice 
were γ-irradiated with a single dose of 400 rads on the same day of injection. Mice were anesthesized 
by inhalation of isoflurane, and were injected with 150 μl cells (5 × 106) per site. Tumors were measured 
in two dimensions by a caliper. Tumor volume was calculated using the formula: V = 0.5 × length × 
width × width. All xenograft data are presented as mean ± SEM. Comparison between groups of 
treatment were conducted using two-tailed Student's t test. Calculations were performed using either 
Openoffice or GraphPad Prism version 5.0b.
For tumorigenesis study, 5 × 106 HMEC cells were injected into the mammary fat pad, and 5 × 106 
Rat1 cells subcutaneously. Tumor growth was monitored twice a week. Rat1 xenografts were harvested 
3 weeks after injection.
To study the impact of MELK knockdown on tumor growth, mice were randomly sorted into groups 
on the second day of injection, and were untreated or treated with doxycycline (2 mg/ml in 5% dextrose 
in drinking water, refreshed twice a week) for the duration of the study. Tumor was measured twice a week.
To study the roles of MELK in tumor maintenance, mice with established tumors (≥200 mm3) derived 
from orthotopic injections of MDA-MB-231, or MDA-MB-468, or MCF-7, or T47D cells were randomly 
sorted into two groups, with one group receiving doxcycline in drinking water. Tumors were calipered 
twice per week to monitor the effect of MELK knockdown on tumor growth.
Time-lapse imaging
Time-lapse imaging was performed on a Nikon Ti motorized inverted microscope, which was equipped 
with a perfect focus system and a humidified incubation chamber (37°C, 5% CO2) (Nikon Imaging 
Center, Harvard Medical School). Cells stably expressing H2B-GFP were pre-seeded in 24-well 
glass-bottom plate, and either untreated or treated with doxycyline (100 ng/ml final). Images were 
captured every 5 min with a 20× objective lens, and a Hamamatsu ORCA-AG cooled CCD camera. 
Images were analyzed using ImageJ (National Institutes of Health).Cell biology | Human biology and medicine
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Immunofluorescence analysis
Cells were seeded on No. 1.5 coverslips (12 mm round) that were pre-placed into 24-well plates. Upon 
harvest, cells were fixed with 4% formaldehyde for 10 min. After washing, cells were permeablized with 
0.1% Trition X-100 for 10 min. Cells were then washed and blocked with 1% bovine serum for 30 min 
before incubated with primary antibody (anti-β-tubulin, #2128; Cell Signaling Technology, Beverly, MA) 
prepared in PBS containing 1% bovine serum albumin. After overnight incubated at 4°C, the samples were 
washed and incubated with Alexa 488-conjugated secondary antibody (Invitrogen) for 1 hr at room tem-
perature. After extensive washing, the samples were dried and mounted with ProLong Antifade reagent 
(Invitrogen). The images were acquired with a Nikon 80i upright microscope at the Nikon Imaging Center 
(Harvard Medical School), which is equipped with a Hamamatsu C8484-03 monochrome camera. ImageJ 
was used for analysis of the images, which includes merging channels with different colors and cropping.
Immunoblotting
Cells were lysed with RIPA buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate) supplemented with protease inhibitors cocktail 
(Roche) and phosphatase inhibitors cocktail (Thermo Scientific, Waltham, MA). Cleared lysates were 
analyzed for protein concentration using BCA kit (Thermo Scientific). Equal amount of protein (10–20 μg) 
was resolved on SDS-PAGE, and was subsequently transferred onto a nitrocellulose or polyvinylidene 
difluoride membrane. The membrane was blocked with 5% non-fat milk and was then incubated with 
primary antibodies overnight at 4°C. After washing, the membrane was incubated with fluorophore-
conjugated secondary antibodies for 1 hr at room temperature. The membrane was then washed 
and scanned with an Odyssey Infrared scanner (Li-Cor Biosciences, Lincoln, NE). Primary antibodies 
used in this study include anti-MELK, anti-α-tubulin (Abcam, Cambridge, MA), anti-cyclin B1 (Millipore), 
anti-Vinculin (Sigma, St. Louis, MO), anti-FoxM1 (Santa Cruz, Dalla, TX), anti-β-tubulin, anti-phopho-
Akt (S473), anti-phospho-Akt (T308), anti-total Akt, anti-Flag, anti-cleaved PARP (Asp214), anti-cleaved 
Caspase-3, anti-AURKA, anti-AURKB, anti-p27, anti-Estrogen Receptor α (all from Cell Signaling 
Technology). Secondary antibodies used were IRDye700-conjugated anti-rabbit IgG and IRDye800-
conjugated anti-mouse IgG (Rockland, Gilbertsville, PA).
Primary human breast cancer samples were obtained from the Dana-Farber Cancer Institute with 
patients' consent and institutional review board approval. These samples were deidentified and are 
not considered human subject research. Samples were homogenized in RIPA buffer supplemented 
with protease/phosphatease inhibitors using Bullet blender (Next advance, Averill Park, NY). After 
clearing, tissue lysates were subjected for protein concentration determination. 20 micrograms of 
lysates were used for immunoblotting.
Generation of Melk knockout mice
Mouse embryonic stem cells with one allele of Melk inserted with lacZ and neomycin-resistance genes 
between exon 2 and 3 were obtained from the Knockout Mouse Project (KOMP; ID: CSD33136). Cells 
with normal karyotype were injected into blastocysts isolated from C57BL/6 mice. The procedure of 
injection was performed at the Transgenic Core Facility, Brigham and Women's Hospital (Boston, MA). 
Germline transmission was subsequently observed, and further cross was made to generate Melk homo-
zygous knockout mice. Melk knockout was confirmed by long-rang PCR, qPCR, and immunoblotting.
Flow cytometry
Cells were isolated from bone marrow, spleen, and thymus of mice, and stained with the following 
antibodies: B220 (APC; BD Pharmingen), cKit (PE-Cy7; BioLegend, San Diego, CA), CD3 (PE-Cy7; BD 
Bioscience), CD4 (APC-H7; BD Pharmingen), CD8 (ECD; Beckman Coulter), CD11b (PE; BD Bioscience), 
CD16/32 (PE; eBioscience, San Diego, CA), CD34 (FITC; BD Pharmingen), CD45.2 (PerCP-Cy5.5; BD 
Pharmingen), CD48 (APC-Cy7; BD Pharmingen), CD127 (ECD; BD Pharmingen), CD150 (PerCP-Cy5.5; 
BioLegend), Gr1 (APC-Alexa700; BD Bioscience), Lineage Cocktail (APC; BD Pharmingen), Sca1 
(Brilliant Violet 421; BioLegend). Dead cells were excluded using either DAPI or Vivid-Aqua (Invitrogen) 
staining. All data acquisition was performed on a LSRII (BD) flow cytometer, and results were analyzed 
using FlowJo v.8.8.7 (TreeStar).
Cell cycle analysis
Cells were harvested by trypsinization, and repeatedly pipetted into single-cell suspension. After cen-
trifugation, cells were fixed by adding 70% ethanol (−20°C) dropwise while vortexing. Cells were then Cell biology | Human biology and medicine
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stained with propidium iodide (50 μg/ml, Sigma) solution containing 50 μg/ml DNase-free RNase A 
(Sigma) and 0.5% bovine serum albumin (BSA). After 30 min of incubation, the samples were washed 
and resuspended in 0.5% BSA. The analysis was performed on a LSRFortessa (BD Biosciences) at the 
DFCI Flow Cytometry Core Facility. Single cells were gated via plotting FL3-A to FL3-H to exclude cell 
debris and doublets. At least 10,000 single cells were collected for each sample.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as previously described (Lee et al., 2006). Upon har-
vest, medium in cell culture dishes was added with 16% formaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) to reach a final concentration of 1%, and quenched with glycine (125 mM final, 5 min 
incubation) after incubation at room temperature for 10 min. Cells were harvested by scrapping into 
cold PBS, and centrifuged. Cell pellets were lysed with LB1 (50 mM HEPES, pH 7.5, 140 mM NaCl, 
1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton-X-100), then after centrifugation with LB2 
(10 mM Tris–HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), and again after centrifugation 
resuspended in LB3 (10 mM Tris–HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% 
Na-Deoxycholate, 0.5% N-lauroylsacosine). Samples were sonicated using a Q800R DNA Shearing 
Sonicator (Qsonica, Newtown, CT) at 50% amplitude for 10 min with a pulse of 30 s on and 30 s off. 
Samples were then supplemented with 10% Triton-X 100 to a final concentration of 1%, and centri-
fuged at 20,000×g for 10 min at 4°C. The cleared lysates were used for the following immunopre-
cipitation, with 50 µl of lysate saved as input.
Protein G-conjugated Dynabeads (Invitrogen) were washed with block solution (0.5% bovine serum 
albumin in PBS) and incubated overnight with 5 µg anti-FoxM1 (SC-502, Santa Cruz Biotechnology), or 
5 µg rabbit IgG in block solution, and on the next day washed three times with block solution. Cell lysates 
were incubated with the antibody/magnetic bead, rotating at 4°C overnight. On the next day, the beads 
were collected with magnetic stand, and washed six times with RIPA buffer (50 mM HEPES pH 7.6, 
500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate). After a single wash with Tris-EDTA buffer 
containing 50 mM NaCl, samples were resupsended with elution buffer (50 mM Tris–HCl pH 8.0, 10 mM 
EDTA, 1% SDS) for incubation at 65°C overnight. Also, the 50 µl input was mixed with 150 µl elution 
buffer and incubated at 65°C overnight for reverse crosslinking. On the next day, RNase A was added to 
the samples (0.2 µg/ml final), followed by incubation for 1 hr at 37°C. Samples were then treated with 
Proteinase K (0.2 µg/ml final) and incubated at 56°C for 1 hr. DNA were purified with a QIAquick PCR 
purification kit (Qiagen), and eluted with 30 µl water. PCR was performed using Quick-Load Taq 2X 
Master Mix (New England BioLabs, Beverly, MA), using primers listed in Supplementary file 2.
qRT-pcr analysis
Total RNA was extracted from cultured cells with RNeasy Mini kit (Qiagen), with the use of 
QIAshredder spin column for homogenization and an on-column DNase digestion. 2 µg of the total 
RNA was reversely transcribed using a High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster 
City, CA). cDNA were analyzed quantitatively using Power SYBR Green PCR Master Mix (Applied 
Biosystems) on an ABI7300 Real-time PCR system. Primers used were listed in Supplementary file 2. 
Cycling conditions were 95°C for 15 min, 40 cycles of 15 s at 94°C, 30 s at 55°C and 30 s at 72°C. Ct 
values were generated using the default analysis settings. ΔCT was defined as Ct gene of interest − Ctβ-actin.   
ΔΔCT was defined as ΔCt treated sample − Ct control sample. Relative quantification (RQ) was calculated as 2−ΔΔCT. 
Statistical analysis was performed by Student's t test.
Analysis of gene expression
Gene expression data were downloaded from Oncomine (Rhodes et al., 2004). Information of the clinical 
data sets is listed in Supplementary file 1. Analyses and figures were made in GraphPad Prism. In dot plot 
graphs, each dot indicates an individual sample, with results expressed as median with interquartile range.
Survival analysis
Independent cohorts of breast cancer patients with overall survival or metastasis-free survival data 
available were examined. Information of the cohorts is listed in Supplementary file 1. Data of MELK 
expression and associated survival were downloaded from Oncomine (Rhodes et al., 2004). For each 
cohort, patients were divided into top 60% ‘MELK high’ and bottom 40% ‘MELK low’ groups based on 
the expression of MELK. Kaplan–Meier curves, as well as the log-rank (Mantel–Cox) test and the haz-
ard ratio were analyzed by GraphPad Prism.Cell biology | Human biology and medicine
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Statistical analysis
Two-tailed Student's t test and ANOVA (Analysis of Variance) were used for differential comparison 
between two groups and among three groups, respectively. Survival and correlation analysis were 
performed in GraphPad Prism.
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